Sofwave

Israeli medical aesthetics company Sofwave received approval from China's NMPA to market its flagship skin-rejuvenation device, targeting a massive non-invasive procedures market.

Medical aesthetics company Sofwave has become a standout performer on the Tel Aviv Stock Exchange. The stock has climbed 48% since the start of 2026 and 320% over the last three years, bringing the company's market value to approximately 1.48 billion shekels.

Sofwave reveals strong financial reports with revenues of approximately 30 million dollars in the second quarter of 2026, alongside a 66% jump in net profit despite one-time expenses.